Elixir Pharmaceuticals Presents Ghrelin Antagonist Program At European Conference On Aging

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the Company’s Chief Scientific Officer, Peter DiStefano, PhD, presented data from its ghrelin antagonist program during the European Conference on Aging held this week in Innsbruck, Austria. Elixir is focused on the development of drugs to treat and prevent metabolic disease, as well as prevent age-related diseases, based on targets identified in the pathways regulating aging. Dr. DiStefano and colleagues, Drs. Rory Curtis and Bard J. Geesaman, have previously authored an extensive review article, titled “Aging and Metabolism: Drug Discovery Opportunities”, which was published in Nature Reviews Drug Discovery (July 2005, Vol. 4, No. 7).